Leap Therapeutics (Leap Therapeutics) 5-Year ROIIC % : 21,342.75% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Leap Therapeutics 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Leap Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was 21,342.75%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Leap Therapeutics's 5-Year ROIIC % or its related term are showing as below:

LPTX's 5-Year ROIIC % is ranked better than
99.57% of 1380 companies
in the Biotechnology industry
Industry Median: -19.115 vs LPTX: 21342.75

Leap Therapeutics 5-Year ROIIC % Historical Data

The historical data trend for Leap Therapeutics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics 5-Year ROIIC % Chart

Leap Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

5-Year ROIIC %

Get a 7-Day Free Trial

-728.34

-16,564.24

51.23

-1,723.33

21,342.75

Leap Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
5-Year ROIIC %	Get a 7-Day Free Trial															-1,723.33	-	-	-	21,342.75

Competitive Comparison of Leap Therapeutics's 5-Year ROIIC %

For the Biotechnology subindustry, Leap Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Leap Therapeutics's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's 5-Year ROIIC % falls into.

Leap Therapeutics 5-Year ROIIC % Calculation

Leap Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %	=	5-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	5-Year Incremental Invested Capital^**
	=	( -85.94 (Dec. 2023) - -30.0219955 (Dec. 2018) )	/	( 1.49 (Dec. 2023) - 1.752 (Dec. 2018) )
	=	-55.9180045	/	-0.26199999999999
	=	21,342.75%^***

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Leap Therapeutics (NAS:LPTX) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Leap Therapeutics 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics (Leap Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (NAS:LPTX) » Definitions » 5-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

5MC:Germany 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.

Executives

Jason Baum	officer: Chief Scientific Officer	LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Patricia A. Martin	director	316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260
Christian M Richard	director	100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110
Richard Schilsky	director	LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Beigene, Ltd.	10 percent owner	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christine Granfield	officer: VP, Head of Reg Affairs/Qual	C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Mark O'mahony	officer: Chief Manufacturing Officer	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Cynthia Sirard	officer: Chief Medical Officer	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher Mirabelli	director, 10 percent owner, officer: CEO,Pres,Chairman of the Board	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Augustine Lawlor	10 percent owner, officer: Chief Operating Officer	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Douglas E Onsi	10 percent owner, officer: CFO,Gen Counsel,Treas, Sec.	C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Healthcare Ventures Ix, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142